Pharsight

Acadia Pharms Inc patents expiration

1. Daybue patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11370755 ACADIA PHARMS INC Compositions of trofinetide
Aug, 2040

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2030
New Chemical Entity Exclusivity (NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

More Information on Dosage

DAYBUE family patents

Family Patents

2. Nuplazid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7923564 ACADIA PHARMS INC Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms
Sep, 2025

(1 year, 11 months from now)

US7732615 ACADIA PHARMS INC N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
Jun, 2028

(4 years from now)

US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9765053 ACADIA PHARMS INC Methods of treatment using selective 5-HT2A inverse agonists
Jul, 2022

(1 year, 2 months ago)

US10028944 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US8921393 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US8618130 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US9566271 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Jan, 2024

(3 months from now)

US7659285 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Aug, 2026

(2 years from now)

US10517860 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

US10953000 ACADIA PHARMS INC Combination of pimavanserin and cytochrome P450 modulators
Mar, 2037

(13 years from now)

US10646480 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US11452721 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US10849891 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

US10449185 ACADIA PHARMS INC Formulations of pimavanserin
Aug, 2038

(14 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof; Tre...

Dosage: TABLET;ORAL

How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage

NUPLAZID family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic